Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Acute Hepatitis C Virus Infection
• MONDO ID: (if available)
• Category: Infectious

Research Objectives

Please provide a comprehensive research report on Acute Hepatitis C Virus Infection covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Acute Hepatitis C Virus (HCV) Infection (Infectious)

Executive summary

Acute (recently acquired) hepatitis C is the first ~6 months after HCV exposure, a period during which infection may spontaneously clear but still frequently progresses to chronic hepatitis C (persistent viremia >6 months). Diagnosis is challenging because most cases are asymptomatic and anti-HCV serology has a window period; nucleic acid testing (NAT) is therefore central. Current expert consensus in major guidance documents supports a “test-and-treat” approach (treat acute infection with standard DAA regimens rather than waiting for spontaneous clearance), while abbreviated short-course regimens (e.g., 6 weeks) are generally not recommended outside trials because of inferior outcomes. (fasano2024acutehepatitisc pages 1-2, liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 2-4, panel2023idsaguidelines pages 9-10)

Table: This table summarizes high-yield evidence for defining, diagnosing, and managing acute hepatitis C virus infection, including diagnostic windows, natural history, risk groups, and current guideline-based treatment. It is useful as a concise knowledge-base-ready abstraction anchored to the gathered evidence contexts.

1. Disease information

1.1 Overview / definition (current understanding)

• Acute / recently acquired HCV infection is generally defined as the first 6 months after initial exposure; chronic HCV infection is defined by persistence of viremia for >6 months. (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)
• The term “acute hepatitis C” is used variably (biological vs clinical definitions are not completely standardized), and many incident infections are clinically silent. (fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)

1.2 Key identifiers and controlled vocabularies

• ICD-10: B17.1 = Acute hepatitis C. (macri2023acuteseverehepatitis pages 2-3)
• ICD-11: Not directly retrievable for acute hepatitis C from the available sources in this run; one GBD-methods paper indicates ICD-11 codes for chronic hepatitis C and sequelae (cirrhosis/HCC), but does not provide a stem code for acute infection. (bai2025globalregionaland pages 1-2)
• MeSH / MONDO: Not directly retrievable from the available sources in this run (no authoritative MeSH descriptor record or MONDO ID located in retrieved evidence). (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 2-4)

1.3 Synonyms / alternative names

• Acute hepatitis C
• Recent(ly) acquired HCV infection
• Incident HCV infection
• Early phase of HCV infection (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 4-5, fasano2024acutehepatitisc pages 2-4)

1.4 Evidence provenance (patient-level vs aggregated)

The information below is derived primarily from aggregated resources (reviews/guidelines, surveillance summaries, GBD analyses, and clinical trial registries), rather than individual EHR case series. (fasano2024acutehepatitisc pages 2-4, zou2024epidemiologyofacute pages 1-2, liu2023acutehepatitisc pages 3-5, NCT03818308 chunk 1)

2. Etiology

2.1 Disease causal factors

• Causative agent: Hepatitis C virus (HCV), a blood-borne, enveloped RNA virus; acute infection follows exposure and may progress to chronic infection with long-term liver disease. (zilouchian2025currentandfuture pages 1-3, fasano2024acutehepatitisc pages 1-2)

2.2 Risk factors

2.2.1 Transmission routes and high-risk populations

Major routes and groups consistently identified: * Parenteral exposure, especially people who inject drugs (PWID) and unsafe medical procedures. (liu2023acutehepatitisc pages 1-3, liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 1-2) * Sexual transmission is particularly important among men who have sex with men (MSM) and people living with HIV (PLWH), often linked to sexual risk behavior and recreational drug use. (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 2-4) * Additional at-risk groups include: intranasal illicit drug users, blood transfusion/transplant recipients before 1992, persons on long-term hemodialysis, and people ever incarcerated. (fasano2024acutehepatitisc pages 2-4)

Quantitative incidence estimates in key populations (examples): * In MSM: pooled HCV incidence in HIV-positive MSM ~8.46/1,000 person-years; in HIV-negative MSM on PrEP ~14.80/1,000 person-years (vs 0.12/1,000 person-years in HIV-negative MSM not on PrEP). (liu2023acutehepatitisc pages 3-5) * In PWID: incidence can be extremely high early after initiation of injecting (up to 133 per 100 person-years in the first year in young PWID, as summarized in a clinical review). (liu2023acutehepatitisc pages 3-5)

2.2.2 Host genetic and immunologic risk/clearance modifiers

A 2023 clinical update summarizes host factors associated with spontaneous clearance (SC) versus progression: * Higher likelihood of SC: female sex; white ethnicity; absence of HIV coinfection; HBV coinfection; IL28B/IFNL3 genotypes rs12979860 CC and rs8099917 TT; specific HLA class II alleles (DQB102, DQB103, DRB104, DRB111); strong HCV-specific T-cell responses; limited quasispecies diversity. (liu2023acutehepatitisc pages 5-6)

2.3 Protective factors

Evidence in the retrieved sources supports that protective factors largely overlap with predictors of spontaneous clearance: * IFNL3/IL28B favorable genotypes and certain HLA class II alleles increase odds of clearance in acute infection. (liu2023acutehepatitisc pages 5-6)

2.4 Gene–environment interactions

Evidence suggests host genotype interacts with immune context and exposure environment: * Sex and interferon-lambda genotype can shape intrahepatic antiviral gene networks and immune response patterns in HCV infection (with implications for outcome variability and response to therapy), highlighting a biologically plausible gene–environment/host–pathogen interaction framework. (toma2025hepatitiscvirus pages 1-2)

3. Phenotypes (clinical features)

3.1 Common clinical presentation

• Asymptomatic infection is common: ~80% of acute infections may be asymptomatic. (liu2023acutehepatitisc pages 5-6)
• Symptomatic acute hepatitis C occurs in a minority; one review reports ~20% symptomatic (fatigue, anorexia, nausea/vomiting, abdominal pain, jaundice). (fasano2024acutehepatitisc pages 4-5)
• Incubation period: ~2–20 weeks (typical ~7 weeks) in reviews. (sallam2024contemporaryinsightsinto pages 10-11)

3.2 Laboratory abnormalities and dynamics

• ALT elevation can be a key clue; supportive diagnostic criteria include ALT >5× ULN. (fasano2024acutehepatitisc pages 2-4)
• Viral kinetics: an early “pre-ramp-up” phase (2–14 days), “ramp-up” (8–10 days), then a “plateau” (45–68 days) has been described in a clinical update (relevant to early-diagnosis challenges). (liu2023acutehepatitisc pages 5-6)

3.3 Rare/severe manifestations

• Acute liver failure is rare in acute HCV, reported as <1% of cases in a 2024 review. (fasano2024acutehepatitisc pages 4-5)

3.4 Suggested HPO terms (mapping suggestions)

These are ontology mapping suggestions for knowledge-base use (not asserted as exhaustive): * Jaundice (HP:0000952) * Fatigue (HP:0012378) * Nausea (HP:0002018) * Vomiting (HP:0002013) * Abdominal pain (HP:0002027) * Elevated hepatic transaminases / Elevated alanine aminotransferase (often represented via “Abnormal liver function test”; lab-phenotype HPO mapping may vary by curation practice)

3.5 Quality-of-life impact

Direct, acute-phase QoL metrics (e.g., SF-36/EQ-5D) were not retrievable from the sources in this run; however, asymptomatic presentation is common, and symptomatic episodes can reduce functioning transiently (fatigue, nausea, jaundice). (fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)

4. Genetic / molecular information

4.1 Causal genes

Acute hepatitis C is not a Mendelian genetic disease; it is caused by HCV infection. Host genetics act mainly as modifiers of clearance and disease course. (liu2023acutehepatitisc pages 5-6)

4.2 Modifier genes / loci supported in retrieved evidence

• IFNL3 / IL28B polymorphisms (e.g., rs12979860, rs8099917) are associated with spontaneous clearance likelihood. (liu2023acutehepatitisc pages 5-6)
• HLA class II alleles (e.g., DQB102, DQB103, DRB104, DRB111) are associated with spontaneous clearance in summarized evidence. (liu2023acutehepatitisc pages 5-6)

4.3 Epigenetics and chromosomal abnormalities

Not specifically retrievable for acute infection from the sources in this run.

5. Environmental information

5.1 Environmental / healthcare-associated factors

• Unsafe medical procedures (e.g., unsafe injections, invasive procedures) remain important in some regions; a clinical update emphasizes ongoing healthcare-associated transmission in some WHO regions. (liu2023acutehepatitisc pages 1-3)

5.2 Lifestyle / behavioral factors

• Injection drug use–related behaviors (shared syringes and preparation equipment, frequent injections, multiple injecting partners) are highlighted as major drivers of transmission. (liu2023acutehepatitisc pages 5-6)

5.3 Infectious agent

• Hepatitis C virus is the relevant infectious agent. (zilouchian2025currentandfuture pages 1-3)

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

1. Exposure and entry: Blood-borne (primarily) exposure introduces HCV; viremia becomes detectable early. (fasano2024acutehepatitisc pages 2-4, liu2023acutehepatitisc pages 5-6)
2. Early replication and innate/adaptive response: Viral RNA rises rapidly; liver inflammation and ALT elevation may follow. (liu2023acutehepatitisc pages 5-6)
3. Outcome bifurcation (clearance vs persistence): A subset clears infection spontaneously (linked to robust CD4+/CD8+ responses and favorable host genetics); the remainder progresses to chronic infection. (liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 4-5)

6.2 Immune system involvement (evidence-based highlights)

• Clearance is associated with broad, multi-specific CD4+ and CD8+ T-cell responses; maintenance of virus-specific CD4+ responses and HCV-specific CD8+ T cells correlate with viral clearance in summarized evidence. (fasano2024acutehepatitisc pages 4-5, fasano2024acutehepatitisc pages 8-10)

6.3 Suggested GO biological process terms (mechanism-oriented)

Mapping suggestions for knowledge-base annotation: * Type I interferon signaling pathway (GO:0060337) / response to virus (GO:0009615) * T cell activation (GO:0042110) * antigen processing and presentation (e.g., GO:0019882)

6.4 Suggested Cell Ontology (CL) terms (cell types)

Mapping suggestions: * Hepatocyte (CL:0000182) * CD4-positive, alpha-beta T cell (CL:0000624) * CD8-positive, alpha-beta T cell (CL:0000625)

6.5 Molecular profiling / omics

• Intrahepatic transcriptional responses vary by host factors; a liver transcriptomics study in HCV identified sex- and IFNL4/IL28B-associated differences in antiviral modules (supporting biologic heterogeneity relevant to outcomes and therapy response). (toma2025hepatitiscvirus pages 1-2)

7. Anatomical structures affected

7.1 Organ/system level

• Primary organ: liver (acute hepatitis). (fasano2024acutehepatitisc pages 4-5)

7.2 Suggested UBERON term

• Liver (UBERON:0002107)

8. Temporal development (natural history)

8.1 Onset and staging

• Viremia detectable by NAT within ~1–2 weeks after exposure; seroconversion typically 4–12 weeks. (fasano2024acutehepatitisc pages 2-4)
• Acute phase is generally defined as ≤6 months post-exposure. (liu2023acutehepatitisc pages 5-6)

8.2 Progression and remission

• Spontaneous clearance occurs in a minority (estimates vary by population and definition), while a large fraction progresses to chronic infection; one review emphasizes ~50–70% progress to chronic infection (viremia >6 months). (fasano2024acutehepatitisc pages 4-5)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

Global burden and incidence (GBD/WHO summaries): * A 2023 clinical update summarizes WHO estimates of ~1.5 million newly acquired HCV infections in 2019, with regional distribution noted (e.g., Eastern Mediterranean ~470k, Europe ~300k). (liu2023acutehepatitisc pages 3-5) * A 2024 GBD-based analysis of reproductive-age women reported that global incidences of acute hepatitis C increased 46.45% from 1990 to 2019 in this demographic. (zou2024epidemiologyofacute pages 1-2)

Europe (surveillance context): * EU/EEA crude reported hepatitis C rate in 2022 was about 6.2 per 100,000 (23,273 cases), with a COVID-era dip and 2022 rebound. (simao2024hepatitiscvirus pages 1-2)

Key populations (PWID): * In 25 European countries, civil-society monitoring notes HCV seroprevalence among PWID ranging 16%–86% and identifies PWID as the main source of new cases. (maticic2024howfarare pages 1-2)

9.2 Demographics

• Males accounted for about 54.6% of new infections in 2019 in summarized global estimates. (liu2023acutehepatitisc pages 3-5)

10. Diagnostics

10.1 Diagnostic concepts and definitions (acute vs chronic)

• Acute diagnosis is most robust when there is HCV RNA positivity with negative anti-HCV (window period) or documented anti-HCV seroconversion within 6 months. (fasano2024acutehepatitisc pages 2-4)
• Anti-HCV positive + HCV RNA positive confirms active infection but does not distinguish acute from chronic without prior testing history. (fasano2024acutehepatitisc pages 2-4)

10.2 Testing windows and algorithms (key data)

• HCV RNA detectability: ~1–2 weeks post-exposure. (fasano2024acutehepatitisc pages 2-4, liu2023acutehepatitisc pages 5-6)
• Anti-HCV antibodies: typically 4–12 weeks, and may be delayed/absent in PLWH, hemodialysis, and transplant recipients—necessitating RNA-based testing. (fasano2024acutehepatitisc pages 2-4)

10.3 Diagnostic algorithm (visual)

Figure evidence for the acute HCV diagnostic algorithm is available here: (fasano2024acutehepatitisc media 039e3907)

10.4 Emerging / improved diagnostics (2023–2024 emphasis)

• A 2024 clinical microbiology study evaluated a dual antibody/core antigen assay (Roche Elecsys HCV Duo) vs standard antibody + NAAT algorithms, noting fourth-generation Ab/Ag assays can shorten the diagnostic window by 2.2–21.9 days vs Ab-only assays; NAAT still detects some Ab−/RNA+ infections missed by serology/Ag. (bui2024comparisonofa pages 2-4, bui2024comparisonofa pages 1-2)

10.5 Differential diagnosis

Acute hepatitis C diagnostic criteria explicitly include exclusion of other causes of acute hepatitis (HAV, HBV, HDV in chronic HBV, autoimmune hepatitis). (fasano2024acutehepatitisc pages 2-4)

11. Outcome / prognosis

11.1 Clearance vs chronicity

• Progression to chronic infection is common; multiple sources report ranges (e.g., 50–70% progressing to chronic, with spontaneous clearance in the remainder). (fasano2024acutehepatitisc pages 4-5, sallam2024contemporaryinsightsinto pages 10-11, liu2023acutehepatitisc pages 5-6)

11.2 Complications

• Acute liver failure is rare (<1%), but untreated chronic infection drives long-term fibrosis/cirrhosis/HCC risk (contextualized in reviews). (fasano2024acutehepatitisc pages 4-5, zilouchian2025currentandfuture pages 1-3)

12. Treatment

12.1 Current guideline position (expert consensus)

• AASLD–IDSA 2023 guidance: treat confirmed acute HCV infection the same as chronic infection and do not wait for spontaneous clearance (“test-and-treat”). (panel2023idsaguidelines pages 9-10)
• The guidance does not recommend abbreviated 6-week DAA courses for acute infection because trials showed inferior responses. (panel2023idsaguidelines pages 9-10)

12.2 Simplified pangenotypic regimens used in practice (including acute)

A 2024 article summarizing AASLD–IDSA 2023 simplified guidance states that the following regimens are suitable for acute or chronic treatment-naive infection under simplified pathways (with standard exclusions such as pregnancy and decompensated cirrhosis): * Glecaprevir/pibrentasvir (G/P): 8 weeks * Sofosbuvir/velpatasvir (SOF/VEL): 12 weeks (pan2024revampinghepatitisc pages 1-2, pan2024revampinghepatitisc pages 2-4)

12.3 Clinical trials and real-world implementation examples (NCT identifiers)

Recent/important acute-HCV DAA trials in ClinicalTrials.gov (illustrative, not exhaustive): * NCT04903626 (AbbVie): Phase 3, single-arm, G/P 8 weeks, n=286, completed 2024-09-17; primary endpoint SVR12. (NCT04903626 chunk 1) * NCT04042740 (ACTG PURGE-C): Phase 2, G/P 4 weeks, n=45, completed; SVR12 primary endpoint; results posted July 2024. (NCT04042740 chunk 1) * NCT03818308 (HepNet-aHCV-V): Phase 2, SOF/VEL 8 weeks, n=20, completed. (NCT03818308 chunk 1) * NCT02128217 (SWIFT-C): Phase 1, HIV-coinfected adults; sofosbuvir-based regimens (SOF+RBV 12 weeks; LDV/SOF 8 weeks), n=44. (NCT02128217 chunk 1)

12.4 MAXO (Medical Action Ontology) term suggestions

Mapping suggestions for curation: * Direct-acting antiviral therapy (MAXO term selection depends on local MAxO release; suggested concept: “antiviral therapy” / “direct-acting antiviral therapy”) * HCV RNA testing (diagnostic action) * Harm-reduction intervention (preventive action)

13. Prevention

13.1 Primary prevention

• Universal precautions, safe injection practices, and harm reduction are repeatedly emphasized in clinical reviews for reducing acute transmission. (liu2023acutehepatitisc pages 1-3, liu2023acutehepatitisc pages 5-6)

13.2 Secondary prevention (screening / early detection)

• AASLD–IDSA-aligned summaries emphasize universal one-time adult screening and repeat/annual screening in high-risk groups, with reflex HCV RNA after antibody testing. (pan2024revampinghepatitisc pages 1-2)

13.3 Vaccine landscape

• No prophylactic HCV vaccine is currently available, and major scientific obstacles include HCV genetic diversity and limited animal models. (liu2023acutehepatitisc pages 1-3, fasano2024acutehepatitisc pages 7-8)

14. Other species / natural disease

Not specifically addressed in retrieved sources for acute infection in this run. (The broader literature includes non-human primate and humanized mouse systems for HCV, but authoritative citations were not retrieved here.)

15. Model organisms

Not specifically addressed in retrieved sources for acute infection in this run.

Notes on evidence gaps (transparent limitations)

• MONDO ID and MeSH descriptor IDs for acute hepatitis C were not found in the retrieved corpus for this run; these would normally be sourced from MONDO/MeSH browser records rather than primary clinical studies. (fasano2024acutehepatitisc pages 2-4)
• ICD-11 acute hepatitis C stem code was not located in the retrieved evidence; ICD-11 was referenced primarily in the context of chronic/sequelae coding in a GBD methods paper. (bai2025globalregionaland pages 1-2)

Key sources (with URLs and publication dates)

• Liu & Kao. Clinical and Molecular Hepatology. July 2023. “Acute hepatitis C virus infection: clinical update and remaining challenges.” https://doi.org/10.3350/cmh.2022.0349 (liu2023acutehepatitisc pages 1-3)
• Fasano et al. Viruses. Nov 2024. “Acute Hepatitis C: Current Status and Future Perspectives.” https://doi.org/10.3390/v16111739 (fasano2024acutehepatitisc pages 1-2)
• Pan & Park. Translational Gastroenterology and Hepatology. Apr 2024. “Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment.” https://doi.org/10.21037/tgh-23-104 (pan2024revampinghepatitisc pages 1-2)
• Bui et al. Journal of Clinical Microbiology. Oct 2024. “Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.” https://doi.org/10.1128/jcm.00832-24 (bui2024comparisonofa pages 2-4)
• Zou et al. Journal of Global Health. Apr 2024. “Epidemiology of acute hepatitis C … in reproductive-age women, 1990–2019 (GBD).” https://doi.org/10.7189/jogh.14.04077 (zou2024epidemiologyofacute pages 1-2)

References

1. (fasano2024acutehepatitisc pages 1-2): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

2. (liu2023acutehepatitisc pages 5-6): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

3. (fasano2024acutehepatitisc pages 2-4): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

4. (panel2023idsaguidelines pages 9-10): AIHCVG Panel. Idsa guidelines. Unknown journal, 2023.

5. (fasano2024acutehepatitisc pages 4-5): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

6. (zilouchian2025currentandfuture pages 4-6): Hussein Zilouchian, Omair Faqah, Md Alamgir Kabir, Dennis Gross, Rachel Pan, Shane Shaifman, Muhammad Awais Younas, Muhammad Abdul Haseeb, Emmanuel Thomas, and Waseem Asghar. Current and future diagnostics for hepatitis c virus infection. Chemosensors, 13:31, Jan 2025. URL: https://doi.org/10.3390/chemosensors13020031, doi:10.3390/chemosensors13020031. This article has 7 citations.

7. (bui2024comparisonofa pages 1-2): Tina I. Bui, Abigail P. Brown, Meghan Brown, Sydney Lawless, Brittany Roemmich, Neil W. Anderson, and Christopher W. Farnsworth. Comparison of a dual antibody and antigen hcv immunoassay to standard of care algorithmic testing. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00832-24, doi:10.1128/jcm.00832-24. This article has 7 citations and is from a peer-reviewed journal.

8. (galli2025hcvserologyan pages 12-13): Claudio Galli and M. Plebani. Hcv serology: an unfinished agenda. Clinical chemistry and laboratory medicine, Aug 2025. URL: https://doi.org/10.1515/cclm-2025-0501, doi:10.1515/cclm-2025-0501. This article has 0 citations and is from a peer-reviewed journal.

9. (sallam2024contemporaryinsightsinto pages 10-11): Malik Sallam and Roaa Khalil. Contemporary insights into hepatitis c virus: a comprehensive review. Microorganisms, 12:1035, May 2024. URL: https://doi.org/10.3390/microorganisms12061035, doi:10.3390/microorganisms12061035. This article has 63 citations.

10. (fasano2024acutehepatitisc pages 7-8): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

11. (kaur2025anexhaustiveupdate pages 4-6): Kulvinder Kochar Kaur, Gautam Nand Allahbadia, and Mandeep Singh. An exhaustive update on eradication of hepatitis c virus (hcv) with the objective of eradicating chronic hepatitis by 2030- a narrative review. Journal of Infectious Diseases & Treatments, pages 1-21, Dec 2025. URL: https://doi.org/10.61440/jidt.2025.v3.48, doi:10.61440/jidt.2025.v3.48. This article has 0 citations.

12. (liu2023acutehepatitisc pages 1-3): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

13. (panel2023idsaguidelines pages 4-5): AIHCVG Panel. Idsa guidelines. Unknown journal, 2023.

14. (fasano2024acutehepatitisc pages 5-7): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

15. (pan2024revampinghepatitisc pages 2-4): Calvin Q. Pan and James S. Park. Revamping hepatitis c global eradication efforts: towards simplified and enhanced screening, prevention, and treatment. Translational Gastroenterology and Hepatology, 9:30-30, Apr 2024. URL: https://doi.org/10.21037/tgh-23-104, doi:10.21037/tgh-23-104. This article has 5 citations and is from a peer-reviewed journal.

16. (pan2024revampinghepatitisc pages 1-2): Calvin Q. Pan and James S. Park. Revamping hepatitis c global eradication efforts: towards simplified and enhanced screening, prevention, and treatment. Translational Gastroenterology and Hepatology, 9:30-30, Apr 2024. URL: https://doi.org/10.21037/tgh-23-104, doi:10.21037/tgh-23-104. This article has 5 citations and is from a peer-reviewed journal.

17. (liu2023acutehepatitisc pages 12-13): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

18. (NCT03818308 chunk 1): Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir. Hannover Medical School. 2019. ClinicalTrials.gov Identifier: NCT03818308

19. (NCT02634008 chunk 1): Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P. Kirby Institute. 2016. ClinicalTrials.gov Identifier: NCT02634008

20. (NCT04903626 chunk 1): Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB). AbbVie. 2021. ClinicalTrials.gov Identifier: NCT04903626

21. (NCT04042740 chunk 1): Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 2019. ClinicalTrials.gov Identifier: NCT04042740

22. (macri2023acuteseverehepatitis pages 2-3): Jennifer Macri, Vanessa Morton, Megan Hame, Pierre-Luc Trépanier, and Marina Salvadori. Acute severe hepatitis of unknown origin in children in canada. Canada Communicable Disease Report, 49:256-262, Jun 2023. URL: https://doi.org/10.14745/ccdr.v49i06a02, doi:10.14745/ccdr.v49i06a02. This article has 3 citations.

23. (bai2025globalregionaland pages 1-2): Junzhu Bai, Hengliang Lv, Longhao Wang, Shumeng You, Dan Liu, Lilin Wang, Yuanyong Xu, Junfeng Lu, and Wenyi Zhang. Global, regional, and national burden of hepatitis c from 1990 to 2021 and projections until 2030. BMC Infectious Diseases, Dec 2025. URL: https://doi.org/10.1186/s12879-025-12396-y, doi:10.1186/s12879-025-12396-y. This article has 0 citations and is from a peer-reviewed journal.

24. (zou2024epidemiologyofacute pages 1-2): Yanzheng Zou, Ming Yue, Xiangyu Ye, Yifan Wang, Xinyan Ma, Amei Zhang, Xueshan Xia, Hongbo Chen, Rongbin Yu, Sheng Yang, and Peng Huang. Epidemiology of acute hepatitis c and hepatitis c virus-related cirrhosis in reproductive-age women, 1990–2019: an analysis of the global burden of disease study. Journal of Global Health, Apr 2024. URL: https://doi.org/10.7189/jogh.14.04077, doi:10.7189/jogh.14.04077. This article has 11 citations and is from a peer-reviewed journal.

25. (liu2023acutehepatitisc pages 3-5): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

26. (zilouchian2025currentandfuture pages 1-3): Hussein Zilouchian, Omair Faqah, Md Alamgir Kabir, Dennis Gross, Rachel Pan, Shane Shaifman, Muhammad Awais Younas, Muhammad Abdul Haseeb, Emmanuel Thomas, and Waseem Asghar. Current and future diagnostics for hepatitis c virus infection. Chemosensors, 13:31, Jan 2025. URL: https://doi.org/10.3390/chemosensors13020031, doi:10.3390/chemosensors13020031. This article has 7 citations.

27. (toma2025hepatitiscvirus pages 1-2): Daniela Toma, Lucreția Anghel, Diana Patraș, and A. Ciubara. Hepatitis c virus: epidemiological challenges and global strategies for elimination. Viruses, Jul 2025. URL: https://doi.org/10.3390/v17081069, doi:10.3390/v17081069. This article has 18 citations.

28. (fasano2024acutehepatitisc pages 8-10): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

29. (simao2024hepatitiscvirus pages 1-2): Margarida Simão and Cristina Gonçalves. Hepatitis c virus infection in europe. Pathogens, 13:841, Sep 2024. URL: https://doi.org/10.3390/pathogens13100841, doi:10.3390/pathogens13100841. This article has 7 citations.

30. (maticic2024howfarare pages 1-2): Mojca Maticic, J. Cernosa, C. Loboda, J. Tamse, R. Rigoni, E. Duffell, I. Indave, R. Zimmermann, L. Darragh, J. Moura, A. Leicht, T. Windelinckx, M. Jauffret-Roustide, K. Schiffer, and T. Tammi. How far are we? assessing progress in hepatitis c response towards the who 2030 elimination goals by the civil society monitoring in 25 european countries, period 2020 to 2023. Harm Reduction Journal, Nov 2024. URL: https://doi.org/10.1186/s12954-024-01115-6, doi:10.1186/s12954-024-01115-6. This article has 3 citations and is from a peer-reviewed journal.

31. (fasano2024acutehepatitisc media 039e3907): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

32. (bui2024comparisonofa pages 2-4): Tina I. Bui, Abigail P. Brown, Meghan Brown, Sydney Lawless, Brittany Roemmich, Neil W. Anderson, and Christopher W. Farnsworth. Comparison of a dual antibody and antigen hcv immunoassay to standard of care algorithmic testing. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00832-24, doi:10.1128/jcm.00832-24. This article has 7 citations and is from a peer-reviewed journal.

33. (NCT02128217 chunk 1): Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 2014. ClinicalTrials.gov Identifier: NCT02128217